Zhao, Rui (Regents of the University of Colorado)
Ford, Heide (Regents of the University of Colorado)
Southall, Noel (NHGRI)
Englund, Erika (NCATS)
Patnaik, Samarjit (NHGRI)
Ferrer-Alegre, Marc (NCATS)
Zheng, Wei (NHGRI)
Dehdashti, Seameen (NCATS)
This technology includes inhibitors of the Eya phosphatase which can be utilized as anticancer therapy. The Eya proteins are essential co-activators of the Six1 transcription factor, a gene that is abnormally re-expressed in a large percentage of breast cancers. This over-expression plays a causal role in the initiation and metastatic development of breast cancers. The Eya family of proteins was also found to contain a unique haloacid dehalogenase phosphatase domain with protein Tyr phosphatase activity which can potentially play a role in Six1- mediated breast tumorigenesis. Recently, Eya was found to dephosphorylate the histone variant H2AX and direct cells to the DNA repair instead of apoptosis pathway in the event of DNA damage.
- Therapy for Six1-mediated breast cancer.
- Utilized as agents that increase the efficiency of radiation and certain chemotherapy agents.
- One in 8 women will be diagnosed with breast cancer in their lifetime and the Six1 gene is over-expressed in 50% of primary breast tumors and 90% of metastatic lesions; large market share.
- Half of patients with cancer receive radiation therapy and selectively sensitizing tumor tissue by engaging the apoptotic program of a cell is of great interest to the field of radiation oncology.